Applied DNA Announces Joint Development Agreement To Integrate Linea IVT Platform Into CDMO Kudo Biotechnology's mRNA Manufacturing Workflow
Portfolio Pulse from Benzinga Newsdesk
Applied DNA Sciences, Inc. (APDN) has entered into a joint development agreement with Kudo Biotechnology to integrate its Linea IVT platform into Kudo Bio's mRNA manufacturing workflow. The collaboration aims to optimize mRNA quality and yields, reduce dsRNA contamination, and shorten manufacturing times. The companies plan to co-market the integrated workflow globally and aim for a commercial launch in the second half of 2024. The Linea IVT Platform is expected to offer significant advantages over conventional methods, including faster turnaround times and scalability.
December 14, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Applied DNA's joint development agreement with Kudo Biotechnology to integrate its Linea IVT platform into mRNA manufacturing could lead to improved product offerings and a competitive edge in the market. The potential commercial launch in 2024 indicates a positive future outlook for the company.
The agreement with Kudo Biotechnology is directly related to Applied DNA's core business and technology. The integration of the Linea IVT platform is likely to enhance the company's product offerings and marketability. The positive impact on APDN's stock is based on the potential for increased revenue and market share in the future, although the actual commercial launch is not immediate and will take place in 2024.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100